Plain-English translation of NCT06114082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a procedure called transarterial chemoembolization (TACE) — a way to deliver strong cancer-fighting drugs directly to tumors in the liver while blocking their blood supply. Researchers want to know whether idarubicin or doxorubicin works better as the medication used in this procedure. You would be randomly assigned to receive one of these two drugs to help determine which one is more effective.
Liver cancer (hepatocellular carcinoma) is difficult to treat, and TACE is a standard option for some patients. However, doctors don't know which chemotherapy drug works best when used in this procedure, so this trial aims to compare the two most commonly considered options to improve treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for a procedure where a thin catheter is guided through your blood vessels to deliver the chemotherapy drug directly into the tumors in your liver. The procedure also involves blocking the blood supply to the tumor with special particles. After your initial treatment, you would have follow-up appointments at 1, 3, and 6 months for imaging and blood tests to see how well the treatment is working. If your tumor comes back or isn't completely gone, your doctors may recommend additional treatments using the same medication.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
South Korea